Epigenetic Changes in Neurodegenerative Diseases

Overview

Journal Mol Cells

Publisher Elsevier

Specialties Cell Biology
Molecular Biology

Date 2016 Nov 23

PMID 27871175

Citations 17

Authors

Min Jee Kwon

Sunhong Kim

Myeong Hoon Han

Sung Bae Lee

Affiliations

Soon will be listed here.

Abstract

Afflicted neurons in various neurodegenerative diseases generally display diverse and complex pathological features before catastrophic occurrence of massive neuronal loss at the late stages of the diseases. This complex nature of neuronal pathophysiology inevitably implicates systemwide changes in basic cellular activities such as transcriptional controls and signal cascades, and so on, as a cause. Recently, as one of these systemwide cellular changes associated with neurodegenerative diseases, epigenetic changes caused by protein toxicity have begun to be highlighted. Notably, recent advances in related techniques including next-generation sequencing (NGS) and mass spectrometry enable us to monitor changes in the post-translational modifications (PTMs) of histone proteins and to link these changes in histone PTMs to the specific transcriptional changes. Indeed, epigenetic alterations and consequent changes in neuronal transcriptome are now begun to be extensively studied in neurodegenerative diseases including Alzheimer's disease (AD). In this review, we will discuss details of our current understandings on epigenetic changes associated with two representative neurodegenerative diseases [AD and polyglutamine (polyQ) diseases] and further discuss possible future development of pharmaceutical treatment of the diseases through modulating these epigenetic changes.

Citing Articles

Roles, Functions, and Pathological Implications of Exosomes in the Central Nervous System.

Spinelli S, Tripodi D, Corti N, Zocchi E, Bruschi M, Leoni V Int J Mol Sci. 2025; 26(3).

PMID: 39941112 PMC: 11818369. DOI: 10.3390/ijms26031345.

Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases.

Yao W, Hu X, Wang X Signal Transduct Target Ther. 2024; 9(1):232.

PMID: 39278916 PMC: 11403012. DOI: 10.1038/s41392-024-01918-w.

Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches.

Shamsi A, Khan M, Yadav D, Shahwan M Front Pharmacol. 2024; 15:1424175.

PMID: 39005934 PMC: 11239971. DOI: 10.3389/fphar.2024.1424175.

DNA Damage and Chromatin Rearrangement Work Together to Promote Neurodegeneration.

Sharma H, Koirala S, Chew Y, Konopka A Mol Neurobiol. 2024; 62(1):1282-1290.

PMID: 38977621 PMC: 11711770. DOI: 10.1007/s12035-024-04331-0.

New Insights into the Gut Microbiota in Neurodegenerative Diseases from the Perspective of Redox Homeostasis.

Wang Y, Zhang Z, Li B, He B, Li L, Nice E Antioxidants (Basel). 2022; 11(11).

PMID: 36421473 PMC: 9687622. DOI: 10.3390/antiox11112287.

References

Igarashi S, Morita H, Bennett K, Tanaka Y, Engelender S, Peters M . Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport. 2003; 14(4):565-8. DOI: 10.1097/00001756-200303240-00007. View

Pallos J, Bodai L, Lukacsovich T, Purcell J, Steffan J, Thompson L . Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet. 2008; 17(23):3767-75. PMC: 2581431. DOI: 10.1093/hmg/ddn273. View

Govindarajan N, Agis-Balboa R, Walter J, Sananbenesi F, Fischer A . Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis. 2011; 26(1):187-97. DOI: 10.3233/JAD-2011-110080. View

Giralt A, Puigdellivol M, Carreton O, Paoletti P, Valero J, Parra-Damas A . Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet. 2011; 21(6):1203-16. DOI: 10.1093/hmg/ddr552. View

Korzus E, Rosenfeld M, Mayford M . CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron. 2004; 42(6):961-72. PMC: 8048715. DOI: 10.1016/j.neuron.2004.06.002. View

Forman M, Trojanowski J, Lee V . Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004; 10(10):1055-63. DOI: 10.1038/nm1113. View

Bobrowska A, Paganetti P, Matthias P, Bates G . Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One. 2011; 6(6):e20696. PMC: 3108987. DOI: 10.1371/journal.pone.0020696. View

Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S . A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal Biochem. 2013; 436(2):112-20. PMC: 4090024. DOI: 10.1016/j.ab.2013.01.035. View

Agis-Balboa R, Pavelka Z, Kerimoglu C, Fischer A . Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. J Alzheimers Dis. 2012; 33(1):35-44. DOI: 10.3233/JAD-2012-121009. View

10.

Jiang H, Poirier M, Liang Y, Pei Z, Weiskittel C, Smith W . Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis. 2006; 23(3):543-51. DOI: 10.1016/j.nbd.2006.04.011. View

11.

Li H, Li S, Yu Z, Shelbourne P, Li X . Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci. 2001; 21(21):8473-81. PMC: 6762783. View

12.

Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof P . Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging. 2013; 34(9):2091-9. PMC: 3955118. DOI: 10.1016/j.neurobiolaging.2013.02.021. View

13.

Frost B, Hemberg M, Lewis J, Feany M . Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014; 17(3):357-66. PMC: 4012297. DOI: 10.1038/nn.3639. View

14.

Nucifora Jr F, Sasaki M, Peters M, Huang H, Cooper J, Yamada M . Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001; 291(5512):2423-8. DOI: 10.1126/science.1056784. View

15.

Sadri-Vakili G, Bouzou B, Benn C, Kim M, Chawla P, Overland R . Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet. 2007; 16(11):1293-306. DOI: 10.1093/hmg/ddm078. View

16.

Fischer L, Culver D, Tennant P, Davis A, Wang M, Castellano-Sanchez A . Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004; 185(2):232-40. DOI: 10.1016/j.expneurol.2003.10.004. View

17.

Coppede F . One-carbon metabolism and Alzheimer's disease: focus on epigenetics. Curr Genomics. 2010; 11(4):246-60. PMC: 2930664. DOI: 10.2174/138920210791233090. View

18.

Robakis N . An Alzheimer's disease hypothesis based on transcriptional dysregulation. Amyloid. 2003; 10(2):80-5. DOI: 10.3109/13506120309041729. View

19.

Moumne L, Campbell K, Howland D, Ouyang Y, Bates G . Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS One. 2012; 7(2):e31080. PMC: 3275566. DOI: 10.1371/journal.pone.0031080. View

20.

Bates E, Victor M, Jones A, Shi Y, Hart A . Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci. 2006; 26(10):2830-8. PMC: 6675170. DOI: 10.1523/JNEUROSCI.3344-05.2006. View